IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Glenn M Chertow, Anna Marie Chang, G Michael Felker...
https://pubmed.ncbi.nlm.nih.gov/38796655/Actively Recruiting
Led by CSL Behring · Updated on 2026-09-21
3110
Participants Needed
566
Research Sites
N/A
Total Duration
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
CONDITIONS
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
T
Trial Registration Coordinator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CSL Behring
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CSL300 (clazakizumab) IV (all doses) | Placebo IV |
|---|---|---|
| What it is | An investigational intravenous treatment using clazakizumab (CSL300), an interleukin-6 (IL-6) inhibitor, given at several dose levels to target chronic inflammation in people with ESKD receiving dialysis. | A matched intravenous placebo that is identical in appearance to CSL300 but lacks the active ingredient; used as the comparator in the trial. |
| Role in trial | Tested as the investigational drug to assess dosing, safety, and effects on cardiovascular outcomes and inflammation. | Serves as the control to measure the benefits and risks of CSL300 by comparison. |
| Primary use | Being studied for its ability to lower inflammation and improve cardiovascular outcomes in adults with ESKD on dialysis who have elevated hs-CRP. | Used as a comparison group to evaluate the actual effect of CSL300 on inflammation and cardiovascular risk. |
| How it is given or performed | Administered through intravenous infusion in addition to regular dialysis care. Dose levels are assigned as per trial part (low, medium, high in phase 2b; fixed in phase 3). | Intravenous infusion with the same schedule and appearance as CSL300, but without the active drug. |
| Evidence status | Phase 2b results show significant reduction in hs-CRP and suggest anti-inflammatory effects, but longer-term effects on cardiovascular events and safety are still being studied in phase 3. | Serves as the control; no known effect on inflammation or cardiovascular events in this context. |
| Important limitations | Long-term cardiovascular efficacy and safety outcomes are not yet available. The phase 3 part is ongoing, and rare risks or effects may be identified only with longer follow-up or in larger populations. | No established benefit; serves only as a comparator to measure the effects and safety of CSL300. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Glenn M Chertow, Anna Marie Chang, G Michael Felker...
https://pubmed.ncbi.nlm.nih.gov/38796655/CSL Behring
Lead Sponsor